Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Set up an appointment as per your flexibility.
February 2025 A study published January 30, 2025, found that medications like Ozempic and Mounjaro, commonly used to treat diabetes and aid in weight loss, may be linked to rare eye conditions that can cause vision loss or even blindness
#AscendisPharma #NovoNordisk #TransConTechnology #MetabolicDiseases #CardiovascularDiseases #Biopharma #HealthcareInnovation #GLP1 bioSeedins Post Ascendis Pharma (Nasdaq: ASND) Ascendis Pharma has granted Novo Nordisk (NYSE: NVO) Novo Nordisk an exclusive license to use its TransCon technology platform for developing treatments in metabolic diseases, including obesity and type 2 diabetes, and on a product-specific basis for cardiovascular diseases
Locate available third-party analytical records and review documented results
In recent, supplements of probiotics have been reported to play a beneficial role in more intro-intestinal or extro-intestinal diseases, such as inflammatory bowel disease (IBD) (41, 42), rheumatic arthritis (43, 44), T2DM (45, 46), chronic kidney disease (CKD) (47, 48), NAFLD (49, 50) and so on
US$ 24.13
US$ 25.25
US$ 20.85
US$ 27.26
US$ 21.55
US$ 27.85
